Effects of etanercept in patients with the metabolic syndrome
Effects of etanercept in patients with the metabolic syndrome
复制标题
DOI：
10.1001/archinte.166.8.902
复制
发表时间：
2006-04-24
影响因子：
--
通讯作者：
Grinspoon, SK
中科院分区：
文献类型：
--
作者：
Bernstein, LE;Berry, J;Grinspoon, SK
背景：脂肪来源的细胞因子，包括肿瘤坏死因子α，可能参与代谢综合征的炎症反应。我们研究了依那西普对代谢综合征患者肿瘤坏死因子α的抑制作用。方法：56例代谢综合征患者随机分为依那西普和安慰剂，每周皮下注射50 mg，共4周。C反应蛋白水平是主要终点。同时测定对其他炎症标志物(包括纤维蛋白原、白介素6和脂联素)、胰岛素敏感性、血脂水平和身体成分的影响。结果：两组基线特征相似。每组有两名受试者退出，依那西普在整个研究过程中耐受性良好。治疗组C反应蛋白水平明显低于安慰剂组(-2.4+/-0.4vs0.5+/-0.7 mg/L；P
Background: Adipose-derived cytokines, including tumor necrosis factor alpha, may contribute to the inflammation that occurs in the metabolic syndrome. We investigated the effects of inhibition of tumor necrosis factor alpha with etanercept in patients with the metabolic syndrome.Methods: Fifty-six subjects with the metabolic syndrome were randomized to administration of either etanercept or identical placebo, 50 mg subcutaneously once a week for 4 weeks. The C-reactive protein level was the primary end point. Effects on other inflammatory markers ( including fibrinogen, interleukin 6, and adiponectin), insulin sensitivity, lipid levels, and body composition were also determined.Results: Baseline characteristics were similar between the groups. Two subjects dropped out of each group, and etanercept was well tolerated throughout the study. The C-reactive protein levels decreased significantly in the treated compared with the placebo group (-2.4 +/- 0.4 vs 0.5 +/- 0.7 mg/ L;P